Medical News

RSS
Primary care doctors ‘not doing enough’ to curb STDs

Primary care doctors ‘not doing enough’ to curb STDs

Study findings could set new standard of care for advanced anal cancer

Study findings could set new standard of care for advanced anal cancer

Stratasys to showcase potential of 3D printed models at MEDICA 2018

Stratasys to showcase potential of 3D printed models at MEDICA 2018

Duration of respiratory disturbances may better predict mortality risk from OSA

Duration of respiratory disturbances may better predict mortality risk from OSA

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award

The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Researchers produce artificial antibody capable of blocking prions in the laboratory

Researchers produce artificial antibody capable of blocking prions in the laboratory

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Educational initiatives needed to improve knowledge about biosimilars in oncology

Educational initiatives needed to improve knowledge about biosimilars in oncology

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

At-home biofeedback therapy effective in relieving difficult-to-treat constipation

At-home biofeedback therapy effective in relieving difficult-to-treat constipation

Canon Medical to showcase world's first Ultra-High Resolution CT system at ASTRO 2018

Canon Medical to showcase world's first Ultra-High Resolution CT system at ASTRO 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.